1. Home
  2. SUPN vs UA Comparison

SUPN vs UA Comparison

Compare SUPN & UA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • UA
  • Stock Information
  • Founded
  • SUPN 2005
  • UA 1996
  • Country
  • SUPN United States
  • UA United States
  • Employees
  • SUPN N/A
  • UA N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • UA Apparel
  • Sector
  • SUPN Health Care
  • UA Consumer Discretionary
  • Exchange
  • SUPN Nasdaq
  • UA Nasdaq
  • Market Cap
  • SUPN 2.6B
  • UA 2.8B
  • IPO Year
  • SUPN 2012
  • UA N/A
  • Fundamental
  • Price
  • SUPN $46.21
  • UA $4.83
  • Analyst Decision
  • SUPN Buy
  • UA
  • Analyst Count
  • SUPN 2
  • UA 0
  • Target Price
  • SUPN $43.00
  • UA N/A
  • AVG Volume (30 Days)
  • SUPN 707.2K
  • UA 6.5M
  • Earning Date
  • SUPN 11-03-2025
  • UA 11-06-2025
  • Dividend Yield
  • SUPN N/A
  • UA N/A
  • EPS Growth
  • SUPN 1411.53
  • UA N/A
  • EPS
  • SUPN 1.14
  • UA 0.23
  • Revenue
  • SUPN $665,125,000.00
  • UA $5,114,713,000.00
  • Revenue This Year
  • SUPN $4.84
  • UA N/A
  • Revenue Next Year
  • SUPN $17.69
  • UA $2.69
  • P/E Ratio
  • SUPN $40.24
  • UA $20.96
  • Revenue Growth
  • SUPN 5.55
  • UA N/A
  • 52 Week Low
  • SUPN $29.16
  • UA $4.62
  • 52 Week High
  • SUPN $46.79
  • UA $10.62
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 73.71
  • UA 34.10
  • Support Level
  • SUPN $44.10
  • UA $4.83
  • Resistance Level
  • SUPN $46.79
  • UA $5.13
  • Average True Range (ATR)
  • SUPN 1.06
  • UA 0.14
  • MACD
  • SUPN -0.17
  • UA 0.04
  • Stochastic Oscillator
  • SUPN 85.92
  • UA 6.06

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About UA Under Armour Inc. Class C

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.

Share on Social Networks: